Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable response rates and revolutionized the treatment of patients suffering from defined hematological malignancies. However, many patients still do not respond to this therapy or relapse after an initial remission, underscoring the ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Stock, Sophia, Kluever, Anna-Kristina, Endres, Stefan, Kobold, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869718/
https://www.ncbi.nlm.nih.gov/pubmed/35203517
http://dx.doi.org/10.3390/biomedicines10020307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869718/
https://www.ncbi.nlm.nih.gov/pubmed/35203517
http://dx.doi.org/10.3390/biomedicines10020307

Ejemplares similares